MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.amjcard.2025.07.022

Медицинская библиотека · The American journal of cardiology · 2025

Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Outcomes.

Chaturvedi Abhishek, Hill Andrew P, Creechan Patrick, Abusnina Waiel, Rappaport Hank, Zhang Cheng, Sawant Vaishnavi, Lupu Lior, Haberman Dan, Rogers Toby, Ben-Dor Itsik, Hashim Hayder D, Satler Lowell F, Case Brian C, Waksman Ron

СтатьяПеревод в очереди

Аннотация

Cangrelor is an intravenous P2Y12 receptor inhibitor. Data on its use as "bailout" therapy for thrombotic complications during percutaneous coronary intervention (PCI) are lacking. We screened patients who received cangrelor as bailout therapy (if not planned upfront, but used for a clinically indicated reason after the first balloon angioplasty or stent deployment) during PCI at our institution from January 2016 through December 2023. Angiographic (thrombolysis in myocardial infarction (TIMI) flow, resolution of thrombus) and in-hospital clinical outcomes - ischemic events (composite of inpatient mortality, target vessel or lesion revascularization, and ischemic stroke), major bleeding (intracranial hemorrhage, blood transfusion for hemoglobin drop >3 g/dL), and length of stay (LOS) - were analyzed. Of 2680 patients receiving cangrelor during PCI, 67 (2.5%) received it as bailout. The mean age was 66.7 years and 73.1% were male. The reasons for cangrelor bailout included slow flow (40.3%), no-reflow (23.9%), stent thrombosis (22.4%), and acute side branch occlusion (16.4%). Cangrelor significantly improved the mean TIMI flow from 1.3 to 2.7 overall and improved flow in all patients with TIMI-0 flow at the time of bailout. In those with stent thrombosis, cangrelor led to complete (86.7%) or partial (13.3%) resolution of the thrombus on the final angiogram. In-hospital ischemic events occurred in 11.9% and major bleeding in 4.5% of patients. The mean LOS was 5.8 days. Among patients undergoing PCI, the use of cangrelor as an ad-hoc bailout strategy is safe, feasible, and may provide an alternative to glycoprotein IIb/IIIa inhibitors.

Для цитирования: Chaturvedi Abhishek, Hill Andrew P, Creechan Patrick, Abusnina Waiel, Rappaport Hank, Zhang Cheng, Sawant Vaishnavi, Lupu Lior, Haberman Dan, Rogers Toby, Ben-Dor Itsik, Hashim Hayder D, Satler Lowell F, Case Brian C, Waksman Ron. Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Outcomes.. The American journal of cardiology. 2025. DOI: 10.1016/j.amjcard.2025.07.022.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.